Delving into the Latest Updates on HYP-6589 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

SOS1

Action

inhibitors

Mechanism

SOS1 inhibitors(Son of sevenless homolog 1 inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Advanced Malignant Solid NeoplasmNon-Small Cell Lung CancerAdvanced Lung Non-Small Cell Carcinoma

Inactive Indication-

Originator Organization

Sichuan Huiyu Seacross Pharma Technology Ltd.

Active Organization

Sichuan Huiyu Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

[Translation] An open-label, multicenter, multi-cohort Phase I/II study evaluating the safety, tolerability, pharmacokinetics, and efficacy of HYP-6589 as a monotherapy in patients with advanced solid tumors and in combination with tyrosine kinase inhibitors in patients with advanced NSCLC who are positive for target driver genes

主要目的：评价HYP-6589单药治疗晚期实体瘤的安全性和耐受性；确定HYP-6589治疗晚期实体瘤患者的推荐II 期剂量（RP2D）和/或最大耐受剂量（MTD）。

[Translation]

Primary objectives: To evaluate the safety and tolerability of HYP-6589 monotherapy in the treatment of advanced solid tumors; to determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) of HYP-6589 in the treatment of patients with advanced solid tumors.

Start Date09 Dec 2024

Sponsor / Collaborator

Sichuan Huiyu Seacross Pharma Technology Ltd.

[+1]

NCT06712680

/ RecruitingPhase 1/2

A Phase I/II , Open-label, Multi-center, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HYP-6589 Monotherapy in Advanced Solid Tumors and Combination With Tyrosine Kinase Inhibitors in Patients With Advanced NSCLC With Target-driven Gene Positivity

This is a multi-center , open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of HYP-6589 in monotherapy in advanced solid tumors and combination with tyrosine kinase inhibitors in patients with advanced NSCLC with target-driven gene positivity.

Start Date27 Nov 2024

Sponsor / Collaborator

Sichuan Huiyu Pharmaceutical Co., Ltd.

100 Clinical Results associated with HYP-6589

Login to view more data

100 Translational Medicine associated with HYP-6589

Login to view more data

100 Patents (Medical) associated with HYP-6589

Login to view more data

100 Deals associated with HYP-6589

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	China	Sichuan Huiyu Pharmaceutical Co., Ltd.	27 Nov 2024
Non-Small Cell Lung Cancer	Phase 2	China	Sichuan Huiyu Pharmaceutical Co., Ltd.	27 Nov 2024
Advanced Lung Non-Small Cell Carcinoma	Phase 1	China	Sichuan Huiyu Pharmaceutical Co., Ltd.	09 Dec 2024